Adam's Take

Blue SARS-CoV-2 Colorized scanning electron micrograph

Adam's Take By Adam Feuerstein

CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Adam's Take By Adam Feuerstein

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Adam's Take By Adam Feuerstein

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Adam's Take By Adam Feuerstein

Why did this small biotech blow up? Because spinning bad drug data never works

Adam's Take By Adam Feuerstein

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Adam's Take By Adam Feuerstein

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Adam's Take By Adam Feuerstein

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Adam's Take By Adam Feuerstein

CytoDyn is in financial and clinical distress, newly filed annual report shows

Adam's Take By Adam Feuerstein

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Adam's Take By Adam Feuerstein

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Adam's Take By Adam Feuerstein

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Adam's Take By Adam Feuerstein

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

Adam's Take By Adam Feuerstein

With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

Adam's Take By Adam Feuerstein

CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

Biotech By Adam Feuerstein

CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Adam's Take By Adam Feuerstein

Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock

Adam's Take By Adam Feuerstein

Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Adam's Take By Adam Feuerstein

Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Adam's Take By Adam Feuerstein

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Adam's Take By Adam Feuerstein

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

transmission electron micrograph covid19

Adam's Take By Adam Feuerstein

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

Adam's Take By Adam Feuerstein

Most Read

Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

STAT’s guide to the most important, beneficial drugs approved in the past decade

ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

Here come the right-to-try profiteers. The FDA is powerless to stop them

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

All Coverage

CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Why did this small biotech blow up? Because spinning bad drug data never works

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Applied Therapeutics’ muted response to a clinical hold speaks volumes

CytoDyn is in financial and clinical distress, newly filed annual report shows

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock

Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

Adam’s Take

Most Read

All Coverage